Business

Rising India Inc (OTCMKTS:RSII) Pushes Further On Cannophen™ Trial To Patients In Ohio, Florida

Rising India Inc (OTCMKTS:RSII) announced recently that it’s partnering with PAO Group’s (OTC:PAOG) Alternative Medicine Centers of America to offer a free trial of Cannophen patients within Ohio. The initiative is open to all patients who apply for the trial at the company’s clinics in the region.

Cannophen is basically an oral capsule made from proportionate ratios of THC, CBD, and other unique strains of terpenes. The drug is designed to help the patients that want to recover from the symptoms of smoking/vaping, or using off-tasting tinctures.

According to COO Arthur Hall, the drug has beneficial elements and it’s effective in treating Parkinson’s symptoms, cancer, and other chronic medical conditions. With the continued use of the Cannophen Hall is declared cancer free. Hall is impressed that the program is extended to patients in Ohio and beyond.

Previous studies indicate that the presence of ‘cannabinoids’ in the cannabis is effective in slowing cancer growth, hampering the development of new blood cells that fuels growth of tumors, and help in alleviating chronic pain, nausea, fatigue, and other chronic side effects.

The program will commence immediately with a Producer/Processor in California starting from next week. The trial has demonstrated the serious interest and the need to license and distribute the Cannophen™ and other Rising Bioscience products that would improve the lives of patients.

According to a study conducted by The National Cancer Institute on mice and rats, the cannabinoids are used to inhibit tumor growth by blocking cell growth, causing cell death, and blocking the development of blood vessels required to accelerate the growth of tumors while protecting normal cells.

Meanwhile, Rising India is nearing completion on the approval of the TWS pain cream products and it’s in the process of partnering with a firm for national distribution of Scar Peptide Serum. The company focuses on producing oral and topical cannabis and non-cannabis-based products using standards set by the pharmaceutical industry.